SLSBio(Specialty Lab Solution Bio)
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
SLSBio provides pharmaceutical quality-testing services, laboratory tests that verify whether a drug meets the safety and efficacy standards required by Korean regulators, and also supports drug-discovery research and develops in-vitro diagnostic test kits.
Its clients include pharmaceutical importers and manufacturers that lack their own testing facilities or expertise. Listed on KOSDAQ, Korea's tech and small-cap board, the company is officially designated by Korea's Ministry of Food and Drug Safety as an authorized contract-testing institution, a status that creates high barriers to entry for new competitors in this field.
Summary is AI-generated and may contain errors · figures from DART filings
The company holds a formal designation from Korea's Ministry of Food and Drug Safety as an authorized pharmaceutical quality-testing institution, a government-granted status required to perform contract testing on behalf of importers.
SLSBio(Specialty Lab Solution Bio) in five facts
What does SLSBio(Specialty Lab Solution Bio) do?
SLSBio provides pharmaceutical quality-testing services, laboratory tests that verify whether a drug meets the safety and efficacy standards required by Korean regulators, and also supports drug-discovery research and develops in-vitro diagnostic test kits.
Where is SLSBio(Specialty Lab Solution Bio) listed and in which sector?
SLSBio(Specialty Lab Solution Bio) (Korean name: 에스엘에스바이오) trades under KRX code 246250 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is SLSBio(Specialty Lab Solution Bio)?
Its market capitalisation was US$22.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were SLSBio(Specialty Lab Solution Bio)'s latest annual revenue and operating profit?
For fiscal year 2025, SLSBio(Specialty Lab Solution Bio) reported revenue of US$3M, an operating loss of US$3.1M and a net loss of US$3.7M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was down 52.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.